Program
Trifluridine
Also written as “Suvemcitug injection, trifluridine/tipiracil tablets”.
Its studies are mostly in Colorectal Neoplasms · Mycobacterium avium-intracellulare Infection, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 10 open or running | no phasesince Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Otsuka | 10 open or running | phase 1since May 24, 2013 | May 24, 2013 | none ahead |
| Simcere Pharmaceutical Group | 11 open or running | phase 3since Sep 30, 2025 | Sep 30, 2025 | Jan 2028phase 3 · NCT07361003 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 1999First study: no phase study in Mycobacterium avium-intracellulare InfectionNew to AmgenAmgen · NCT00002037 · 15 enrolled · United States
- May 24, 2013Otsuka's first study: phase 1 study in Advanced Solid TumorsNew to OtsukaOtsuka · NCT01867866 · 44 enrolled · United States
- Sep 30, 2025Simcere Pharmaceutical Group's first study: phase 3 study in Colorectal NeoplasmsNew to Simcere Pharmaceutical GroupSimcere Pharmaceutical Group · NCT07361003 · 464 planned · China
Ahead
- Jan 2028Primary completion: phase 3 study in Colorectal NeoplasmsSimcere Pharmaceutical Group · NCT07361003
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA inhibitor”ChEMBL 37, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07361003Colorectal Neoplasms · China | 3 | Recruiting | Simcere Pharmaceutical Group | Jan 2028 | 464 |
| NCT01867866Advanced Solid Tumors · United States | 1 | Completed | Otsuka | Oct 2013 | 44 |
| NCT00002037Mycobacterium avium-intracellulare Infection · United States | – | Completed | Amgen | 15 |
How it is read
Names in the registry
- “Trifluridine”, 2 entries
- “Suvemcitug injection, trifluridine/tipiracil tablets”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
- Mycobacterium avium-intracellulare Infection, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.